In the attempts to improve CAR T-cell function, Neville Sanjana told BioWorld Science, "most of the focus is on making the CAR better."

After securing $70 million in series B funding, Chinese biotech Medilink Therapeutics Co. Ltd. is gearing up to enter the clinic with its next-generation antibody-drug conjugates (ADCs).